Cover Image
市場調查報告書

煙酰胺磷酸:開發平台分析

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 359834
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
煙酰胺磷酸:開發平台分析 Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016
出版日期: 2016年05月18日 內容資訊: 英文 46 Pages
簡介

本報告提供以煙酰胺磷酸為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

煙酰胺磷酸概要

治療藥的開發

煙酰胺磷酸:開發中的產品 - 各開發階段

煙酰胺磷酸:開發中的產品 - 各治療範圍

煙酰胺磷酸:開發中的產品 - 各適應症

煙酰胺磷酸:開發中產品概況

  • 初期階段的產品

煙酰胺磷酸:企業開發中的產品

煙酰胺磷酸:大學/機關開發中的產品

煙酰胺磷酸:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

煙酰胺磷酸的治療藥開發企業

  • Angelini Group
  • Aurigene Discovery Technologies Limited
  • Calico LLC
  • FORMA Therapeutics, Inc.
  • Genentech, Inc.
  • Karyopharm Therapeutics, Inc.
  • OncoTartis, Inc.

藥物簡介

煙酰胺磷酸:暫停中的計劃

煙酰胺磷酸:開發中止的產品

煙酰胺磷酸:主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0040TDB

Summary

Global Markets Direct's, 'Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016', provides in depth analysis on Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted pipeline therapeutics.

The report provides comprehensive information on the Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12)
  • The report reviews Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) Overview
    • Therapeutics Development
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Stage of Development
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Therapy Area
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Indication
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Products Glance
    • Early Stage Products
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Companies
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Universities/Institutes
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Companies Involved in Therapeutics Development
    • Angelini Group
    • Aurigene Discovery Technologies Limited
    • Calico LLC
    • FORMA Therapeutics, Inc.
    • Genentech, Inc.
    • Karyopharm Therapeutics, Inc.
    • OncoTartis, Inc.
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Drug Profiles
    • AU-4869 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit NAMPT for Inflammation and Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNE-617 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPT-9274 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OT-82 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P- BEFizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P7-C3A20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NAMPT for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STF-118804 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Dormant Projects
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Discontinued Products
  • Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Featured News & Press Releases
    • Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting
    • Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015
    • Nov 01, 2013: Novel drug discovery method designed by Stanford scientists
    • Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Angelini Group, H1 2016
  • Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Pipeline by Calico LLC, H1 2016
  • Pipeline by FORMA Therapeutics, Inc., H1 2016
  • Pipeline by Genentech, Inc., H1 2016
  • Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Pipeline by OncoTartis, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top